Jump to main content
Jump to site search

Issue 5, 2015
Previous Article Next Article

Recent discoveries and developments of androgen receptor based therapy for prostate cancer

Author affiliations

Abstract

The main focus of this review is to discuss the discoveries and developments of various therapies for prostate cancer. The AR has played an important role in prostate cancer growth and functions. This review discusses several groups of drugs that have sparingly good anti-cancer activities, as well as a similar structure and behaviour. A recent new-generation AR antagonist, Enzalutamide (MDV3100), has been approved for the treatment of advanced/metastatic prostate cancer. Nonsteroidal antiandrogens represent an important class of molecules acting as either antagonists or agonists. Recently, many therapeutic agents for prostate cancer that target the androgen receptor and reduce prostate tumour growth have been approved. The strong response to this new use of Enzalutamide provides a viable, less toxic alternative to chemotherapy. The current status of prostate cancer drugs are discussed here, but it is evident that considerably more work is needed for improvements in respect to efficacy, reduction of the side effects and treatment strategies.

Graphical abstract: Recent discoveries and developments of androgen receptor based therapy for prostate cancer

Back to tab navigation

Publication details

The article was received on 17 Sep 2014, accepted on 19 Dec 2014 and first published on 05 Jan 2015


Article type: Review Article
DOI: 10.1039/C4MD00416G
Author version
available:
Download author version (PDF)
Med. Chem. Commun., 2015,6, 746-768

  •   Request permissions

    Recent discoveries and developments of androgen receptor based therapy for prostate cancer

    R. Elancheran, V. L. Maruthanila, M. Ramanathan, S. Kabilan, R. Devi, A. Kunnumakara and J. Kotoky, Med. Chem. Commun., 2015, 6, 746
    DOI: 10.1039/C4MD00416G

Search articles by author

Spotlight

Advertisements